<DOC>
	<DOCNO>NCT01680341</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe United States America ( USA ) . The aim trial compare efficacy safety two different titration algorithm insulin degludec/insulin aspart ( IDeg/IAsp ) subject type 2 diabetes mellitus previously treat insulin glargine .</brief_summary>
	<brief_title>Comparison Efficacy Safety Two Different Dose Adjustment Regimens Insulin Degludec/Insulin Aspart Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) least 24 week prior Visit 2 ( randomisation ) Currently treat IGlar ( Insulin Glargine ) 3 oral antidiabetic drug ( OADs ) ( metformin , DPP4 inhibitor , sulphonylurea/glinide alphaglucosidase inhibitor ) . All antidiabetic treatment ongoing least 12 week prior Visit 2 ( randomisation ) dose stable period time Glycosylated haemoglobin ( HbA1c ) 7.010.0 % ( inclusive ) central laboratory analysis Body mass index ( BMI ) equal 40 kg/m^2 Treatment glucagonlike peptide 1 ( GLP1 ) receptor agonist thiazolidinediones ( TZDs ) within last 12 week prior Visit 2 ( randomisation ) Stroke ; heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty ; within last 24 week prior Visit 2 ( randomisation ) Uncontrolled untreated severe hypertension define systolic blood pressure equal 180 mmHg and/or diastolic blood pressure equal 100 mmHg Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge investigator Lifethreatening disease ( e.g . cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>